Ot­su­ka pens AAV deal with Shape Ther­a­peu­tics for eye gene ther­a­pies

Japan­ese phar­ma­ceu­ti­cal com­pa­ny Ot­su­ka has en­list­ed Seat­tle-based RNA edit­ing biotech Shape Ther­a­peu­tics to de­vel­op new ade­no-as­so­ci­at­ed virus (AAV) vec­tors. The hope is to find new ways to de­liv­er gene ther­a­pies to treat eye dis­eases.

Shape and Ot­su­ka de­clined to dis­close the up­front pay­ment, but the deal is po­ten­tial­ly worth more than $1.5 bil­lion to­tal, in­clud­ing de­vel­op­ment, reg­u­la­to­ry and sales mile­stones. Shape is al­so el­i­gi­ble to re­ceive roy­al­ties on a gene ther­a­py that us­es its AAVs. The new AAVs will be used to de­vel­op one-time ther­a­pies in­ject­ed in­to the whites of the eye, but the part­ners de­clined to dis­close what dis­eases or tar­gets the col­lab­o­ra­tion is for.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER